Objective: To provide recommendations on appropriate uses for serum markers of germ cell tumors (GCTs).
Methods: Searches of MEDLINE and EMBASE identified relevant studies published in English. Primary outcomes included marker accuracy to predict impact of decisions on outcomes. Secondary outcomes included proportions with elevated markers, and statistical tests of elevations as prognostic factors. An expert panel developed consensus guidelines based on data from 81 reports.
Results: No studies directly compared outcomes of decisions with versus without marker assays. The search identified few prospective studies and no RCTs; most were retrospective series. Lacking data on primary outcomes, most Panel recommendations are based on secondary outcomes (relapse rates and time to relapse).
Recommendations: The Panel recommended against using markers to screen for GCTs, to decide whether orchiectomy is indicated, or to select treatment for patients with cancer of unknown primary. To stage patients with testicular non-seminomas, the Panel recommended measuring three markers (AFP, hCG, and LDH) before and after orchiectomy, and before chemotherapy for those with extra-gonadal non-seminomas. They also recommended measuring AFP and hCG shortly before retroperitoneal lymph node dissection and at the start of each chemotherapy cycle for non-seminoma, and periodically to monitor for relapse. The Panel recommended measuring post-orchiectomy hCG and LDH for patients with seminoma and pre-orchiectomy elevations. They recommended against using markers to guide or monitor treatment for seminoma or to detect relapse in those treated for stage I. However, they recommended measuring hCG and AFP to monitor for relapse in patients treated for advanced seminoma.
To discuss this guideline, visit the ASCOconnection.org Practice forum. Log in with your asco.org username and password to comment.
ASCO’s practice guidelines reflect expert consensus based on clinical evidence and literature available at the time they are written and are intended to assist physicians in clinical decision-making and identify questions and settings for further research. Due to the rapid flow of scientific information in oncology, new evidence may have emerged since the time a guideline was submitted for publication. Guidelines are not continually updated and may not reflect the most recent evidence. Guidelines address only the topics specifically identified in the guideline and are not applicable to interventions, diseases or stages of disease not specifically identified. Guidelines cannot account for individual variation among patients and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It is the responsibility of the treating physician or other health care provider, relying on independent experience and knowledge of the patient, to determine the best course of treatment for the patient. Accordingly, adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made by the physician in light of each patient's individual circumstances and preferences. ASCO guidelines describe the use of procedures and therapies in clinical practice and cannot be assumed to apply to the use of these interventions in the context of clinical trials. ASCO assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of ASCO's guidelines, or for any errors or omissions.
Last Updated: 6/7/10
